Mark Bach

Company: GentiBio

Job title: Chief Medical Officer

Seminars:

Panel Discussion: Evaluating the Future of Autologous & Allogeneic Therapies 11:30 am

Identify the optimal approach to maximize therapeutic efficacy Consider patient safety by addressing challenges related to rejection and adverse immune responses in both autologous and allogeneic therapies Evaluate if autologous or allogeneic therapies are best for future autoimmune therapy personalizationRead more

day: Conference Day Two Pink Track

Harnessing Insights from GentiBio’s Hypo-Immune Allogeneic Cell Therapy Platform to Advance Allogeneic Cell Therapies 12:45 pm

Explore GNTI-122 autologous Type 1 Diabetes therapy Discuss GentiBio’s GNTI-350 hypo-immune allogeneic therapy to uncover key data guiding next-generation autoimmune treatment Evaluate the unique characteristics of hypo-immune allogeneic cell therapies over traditional allogeneic approaches Apply translational insights to accelerate the progression of allogeneic therapies for autoimmune indicationsRead more

day: Conference Day Two Pink Track